Recurrent Melanoma Completed Phase 2 Trials for Pazopanib (DB06589)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00861913Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by SurgeryTreatment